Natural killer cells in haematopoietic stem cell transplantation

Transfusion Medicine

Volumn 13, Issue 6, 2003, Pages 399-404

  Lowdell, Mark W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anti viral immunity; Graft versus host disease; Graft versus leukaemia; Immunotherapy; NK cells

Indexed keywords

INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD; CANCER IMMUNOLOGY; CELL ACTIVATION; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPATHOGENESIS; LEUKEMIA; NATURAL KILLER CELL; POSTOPERATIVE PERIOD; REGULATORY MECHANISM; REVIEW; VIRUS IMMUNITY;

ANIMALS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GRAFT REJECTION; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LEUKEMIA; MICE;

EID: 0346118837     PISSN: 09587578     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3148.2003.00467.x     Document Type: Review

References (30)

1. Acevedo, A., Aramburu, J., Lopex, J. & Fernandez-Herrera, J., Fernandez-Ranada, J.M. & Lopez-Botet, M. (1991) Identification of natural killer cells in lesions of human cutaneous graft-versus-host disease: expression of a novel NK-associated surface antigen (Kp443) in mononuclear infiltrates. The Journal of Investigative Dermatology, 97, 659-666.
2. Adler, A., Chervenick, P.A., Whiteside, T., Lotzova, E. & Herberman, R.B. (1988) Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukaemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood, 71, 709-716.
3. Benyunes, M.C., Massumoto, C., York, A., Higuchi, C.M., Buckner, C.D., Thomson, J.A., Petersen, F.B. & Fefer, A. (1993) Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant, 12, 159-163.
4. bright subset. Blood, 97, 3146-3151.
5. Cudkowicz, G. & Bennett, M. (1971) Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F1 hybrid mice. Journal of Experimental Medicine, 134, 1513-1528.
6. Fletcher, J.M., Prentice, H.G. & Grundy, J.E. (1998) NK cell lysis of CMV-infected cells correlates with virally induced changes in cell surface LFA-3 expression and not with CMV-induced downregulation of surface class I HLA. Journal of Immunology, 161, 2365-2747.
7. Frohn, C., Hoppner, M., Schlenke, P., Kirchner, H., Koritke, P. & Luhm, J. (2002) Anti-myeloma activity of natural killer lymphocytes. British Journal of Haematology, 119, 660-664.
8. Goodman, M., Cabral, L. & Cassileth, P. (1998) Interleukin-2 and leukemia. Leukemia, 12, 1671-1675.
9. Gottlieb, D.J., Brenner, M.K., Heslop, H., Bianchi, A.C.M., Bello-Fernandez, A.B., Mehta, A.B., Newland, A.C., Galazka, A.R., Scott, E.M., Hoffbrand, A.V. & Prentice, H.G. (1989) A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. British Journal of Cancer, 60, 610-615.
10. Gottlieb, D.J., Prentice, H.G., Mehta, A.B., Galazka, A.R., Heslop, H.E., Hoffbrand, A.V. & Brenner, M.K. (1990) Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. British Journal of Haematology, 75, 499-505.
11. Hauch, M., Gazzola, M.V., Small, T., Bordignon, C., Barnett, L., Cunningham, I., Castro-Malaspinia, H., O'Reilly, R.J. & Keever, C.A. (1990) Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood, 75, 2250-2262.
12. Kos, F.J. & Engleman, E.G. (1996) Role of natural killer cells in the generation of influenza virus-specific cytotoxic T cells. Cell Immunology, 173 (1), 1-6.
13. Lanier, L.L. (1998) NK cell receptors. Annual Revue of Immunology, 16, 359-393.
14. Lauria, F., Raspadori, L.F., Rondelli, D., Ventura, M.A. & Foa, R. (1994) In vitro susceptibility of acute leukaemia cells to the cytolytic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia, 8, 724-728.
15. Leger, O., Drexler, H.G., Reittie, J.E., Secker-Walker, L., Prentice, H.G. & Brenner, M.K. (1987) Interleukin 2 enhances cytotoxic cell function in vitro after T-cell depleted marrow transplantation. British Journal of Haematology, 67, 273-279.
16. Lowdell, M.W., Craston, R., Ray, N., Koh, M., Galatowicz, G. & Prentice, H.G. (1998) The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia. Bone Marrow Transplant, 21, 679-686.
17. Lowdell, M.W., Ray, N., Craston, R., Corbett, T., Deane, M. & Prentice, H.G. (1997) The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transplant, 19, 891-897.
18. Lowdell, M.W., Shamim, F., Hamon, M., Macdonald, I.D. & Prentice, H.G. (1995) VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Experimental Hematology, 23, 1530-1534.
19. Mackinnon, S., Hows, J.M. & Goldman, J.M. (1990) Induction of vitro graft-versus-leukaemia activity following BMT for chronic myeloid leukemia. Blood, 76, 2037-2045.
20. Moretta, A. & Moretta, L. (1997) HLA class I specific inhibitory receptors. Current Opinion in Immunology, 9, 694-701.
21. Oblakowski, P., Bello-Fernandez, C., Rettie, J.E., Heslop, H.E., Galatowicz, G., Veys, P., Wilkes, S., Prentice, H.G., Hazelhurst, G., Hoffbrand, A.V. & Brenner, M. (1991) Possible mechanisms of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. Blood, 77, 1006-2001.
22. Petersdorf, E.W. (1997) Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood, 89, 1818-1823.
23. Reittie, J., Gottlieb, D., Heslop, H. et al. (1989) Endogenously generated activated killer cells after autologous and allogeneic marrow transplantation. Blood, 73, 1351-1358.
24. Robertson, L.E., Denny, A.W., Huh, Y.O., Plunkett, W., Keating, M.J. & Nelson, J.A. (1996) Natural killer cell activity in chronic lymphocytic leukaemia patients treated with fludarabine. Cancer Chemotherapy and Pharmacology, 37, 445-450.
25. Ruggeri, L. et al. (2002) Effectiveness of donor natural killer cell alloreactivity in HLA mismatched hematopoietic transplants. Science, 295, 2097-2100.
26. Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R.S., Martelli, M.F. & Velardi, A. (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood, 94, 333-339.
27. Silla, L.M.R., Whiteside, T.L. & Ball, E.D. (1995) The role of natural killer cells in the treatment of chronic myeloid leukemia. Journal of Hematotherapy, 4, 269-279.
28. Torelli, G.F., Guarini, A., Palmieri, G., Breccia, M., Vitale, A., Santoni, A. & Foa, R. (2002) Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in haematological remission. British Journal of Haematology, 116, 299-307.
29. Valiante, N.M. & Parham, P. (1997) Natural killer cells, HLA class I molecules, and marrow transplantation. Biology of Blood and Marrow Transplantation, 3, 229-235.
30. Yu, Y.Y.L., George, T., Dorfman, J.R., Roland, J., Kumar, V. & Bennett, M. (1996) The role of Ly49A and 5E6 Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity, 4, 67-76.